RetinalGenix Technologies Inc. (RTGN)
OID · Healthcare · Medical Devices
Closing price as of 2026-07-28 · Source: TEK2day Finance
Key Metrics
About RetinalGenix Technologies Inc.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97K | |||
| Operating Income | -648K | -568K | -622K | -589K |
| Net Income | -649K | -569K | -623K | -590K |
| Diluted EPS | $-0.03 | $-0.03 | $nan | $-0.03 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -371K | -404K | -704K | -639K |
| Operating Income | -1.9M | -2.1M | -4.3M | -2.4M |
| Net Income | -3.9M | -2.1M | -4.3M | -2.4M |
| Diluted EPS | $-0.25 | $-0.12 | $-0.24 | $-0.13 |